Diabetes, Vol 49, Issue 5 857-862, Copyright © 2000 by American Diabetes Association

ARTICLES

Nitric oxide synthesis and isoprostane production in subjects with type 1 diabetes and normal urinary albumin excretion

S O'Byrne, P Forte, LJ Roberts, JD Morrow, A Johnston, E Anggard, RD Leslie and N Benjamin
Department of Clinical Pharmacology, St Bartholomew's and the Royal London School of Medicine and Dentistry, Charterhouse Square, UK. s.r.o'byrne@mds.qmw.ac.uk

The role of nitric oxide (NO) and free radicals in the development of microvascular disease in type 1 diabetes remains unclear. We have measured NO and isoprostane (a stable marker of in vivo lipid peroxidation) production in 13 type 1 diabetic subjects with normal urinary albumin excretion and 13 healthy volunteers. Whole-body NO synthesis was quantified by measuring the urinary excretion of 15N-nitrate after the intravenous administration of L-[15N]2-arginine. The urinary excretion of the major urinary metabolite of 15-F2t-isoprostane (8-iso-prostaglandin-F2alpha), 2,3-dinor-5,6-dihydro-F2t-IsoP, was quantified as a marker of in vivo lipid peroxidation. Whole-body NO synthesis was significantly higher in diabetic subjects compared with control subjects (342 vs. 216 nmol 15N-nitrate/mmol creatinine [95% CI of the difference 45-207], P = 0.005). This increase was not explained by a difference in renal function between the 2 groups. There was no difference in 2,3-dinor-5,6-dihydro-F2t-IsoP excretion between diabetic subjects and control subjects (44.8+/-7.8 vs. 41.4+/-10.0 ng/mmol creatinine, mean +/- 95% CI). However, there was an inverse correlation between NO synthesis and free radical activity in subjects with diabetes (r = -0.62, P = 0.012) that was not observed in control subjects (r = 0.37, P = 0.107). We conclude that whole-body NO synthesis is higher in type 1 diabetic subjects with normal urinary albumin excretion than in control subjects. The inverse correlation between isoprostane production and NO synthesis in diabetic subjects is consistent with the hypothesis that NO is being inactivated by reactive oxygen species.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. L. Onozato, A. Tojo, J. Leiper, T. Fujita, F. Palm, and C. S. Wilcox Expression of NG,NG-Dimethylarginine Dimethylaminohydrolase and Protein Arginine N-Methyltransferase Isoforms in Diabetic Rat Kidney: Effects of Angiotensin II Receptor Blockers Diabetes, January 1, 2008; 57(1): 172 - 180. [Abstract] [Full Text] [PDF]

				K. B. Moore Glucose fluctuations and oxidative stress. JAMA, October 11, 2006; 296(14): 1730 - 1730. [Full Text] [PDF]

				L. Monnier, E. Mas, C. Ginet, F. Michel, L. Villon, J.-P. Cristol, and C. Colette Glucose Fluctuations and Oxidative Stress--Reply JAMA, October 11, 2006; 296(14): 1730 - 1731. [Full Text] [PDF]

				E. B. Sochett, D. Z.I. Cherney, J. R. Curtis, M. G. Dekker, J. W. Scholey, and J. A. Miller Impact of Renin Angiotensin System Modulation on the Hyperfiltration State in Type 1 Diabetes J. Am. Soc. Nephrol., June 1, 2006; 17(6): 1703 - 1709. [Abstract] [Full Text] [PDF]

				B. F. Schrijvers, A. S. De Vriese, and A. Flyvbjerg From Hyperglycemia to Diabetic Kidney Disease: The Role of Metabolic, Hemodynamic, Intracellular Factors and Growth Factors/Cytokines Endocr. Rev., December 1, 2004; 25(6): 971 - 1010. [Abstract] [Full Text] [PDF]

				C. D. A. Stehouwer Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease Nephrol. Dial. Transplant., April 1, 2004; 19(4): 778 - 781. [Full Text] [PDF]

				N. N. Chan, P. Vallance, and H. M. Colhoun Endothelium-Dependent and -Independent Vascular Dysfunction in Type 1 Diabetes: Role of Conventional Risk Factors, Sex, and Glycemic Control Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1048 - 1054. [Abstract] [Full Text] [PDF]

				R. D. Hoeldtke, K. D. Bryner, D. R. McNeill, S. S. Warehime, K. Van Dyke, and G. Hobbs Oxidative Stress and Insulin Requirements in Patients with Recent-Onset Type 1 Diabetes J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1624 - 1628. [Abstract] [Full Text] [PDF]

				A. Avogaro, G. Toffolo, E. Kiwanuka, S. V. de Kreutzenberg, P. Tessari, and C. Cobelli L-Arginine-Nitric Oxide Kinetics in Normal and Type 2 Diabetic Subjects: A Stable-Labelled 15N Arginine Approach Diabetes, March 1, 2003; 52(3): 795 - 802. [Abstract] [Full Text] [PDF]

				R. D. Hoeldtke, K. D. Bryner, D. R. McNeill, G. R. Hobbs, J. E. Riggs, S. S. Warehime, I. Christie, G. Ganser, and K. Van Dyke Nitrosative Stress, Uric Acid, and Peripheral Nerve Function in Early Type 1 Diabetes Diabetes, September 1, 2002; 51(9): 2817 - 2825. [Abstract] [Full Text] [PDF]